Literature DB >> 20577269

Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.

Susan Zolla-Pazner1, Timothy Cardozo.   

Abstract

One of the main challenges of developing an HIV-1 vaccine lies in eliciting immune responses that can overcome the antigenic variability exhibited by HIV. Most HIV-1 vaccine development has focused on inducing immunity to conserved regions of the HIV-1 envelope. However, new studies of the sequence-variable regions of the HIV-1 gp120 envelope glycoprotein have shown that there are conserved immunological and structural features in these regions. Recombinant immunogens that include these features may provide the means to address the antigenic diversity of HIV-1 and induce protective antibodies that can prevent infection with HIV-1.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20577269      PMCID： PMC3167078          DOI： 10.1038/nri2801

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN： 1474-1733            Impact factor:   53.106


  103 in total

1.  Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

Authors:  B Labrosse; C Treboute; A Brelot; M Alizon
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Soluble CD4 broadens neutralization of V3-directed monoclonal antibodies and guinea pig vaccine sera against HIV-1 subtype B and C reference viruses.

Authors:  Xueling Wu; Anna Sambor; Martha C Nason; Zhi-Yong Yang; Lan Wu; Susan Zolla-Pazner; Gary J Nabel; John R Mascola
Journal:  Virology       Date:  2008-09-18       Impact factor: 3.616

3.  Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41.

Authors:  M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

4.  V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.

Authors:  A Ly; L Stamatatos
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate.

Authors:  M W Cho; M K Lee; C H Chen; T Matthews; M A Martin
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Molecular architecture of native HIV-1 gp120 trimers.

Authors:  Jun Liu; Alberto Bartesaghi; Mario J Borgnia; Guillermo Sapiro; Sriram Subramaniam
Journal:  Nature       Date:  2008-07-30       Impact factor: 49.962

7.  Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Authors:  James M Binley; Elizabeth A Lybarger; Emma T Crooks; Michael S Seaman; Elin Gray; Katie L Davis; Julie M Decker; Diane Wycuff; Linda Harris; Natalie Hawkins; Blake Wood; Cory Nathe; Douglas Richman; Georgia D Tomaras; Frederic Bibollet-Ruche; James E Robinson; Lynn Morris; George M Shaw; David C Montefiori; John R Mascola
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

8.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

9.  Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.

Authors:  Ralph Pantophlet; Terri Wrin; Lisa A Cavacini; James E Robinson; Dennis R Burton
Journal:  Virology       Date:  2008-09-26       Impact factor: 3.616

10.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321
View more
  96 in total

1.  Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals.

Authors:  Miroslaw K Gorny; Ruimin Pan; Constance Williams; Xiao-Hong Wang; Barbara Volsky; Timothy O'Neal; Brett Spurrier; Jared M Sampson; Liuzhe Li; Michael S Seaman; Xiang-Peng Kong; Susan Zolla-Pazner
Journal:  Virology       Date:  2012-03-07       Impact factor: 3.616

Review 2.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 3.  Prospects for an HIV vaccine: leading B cells down the right path.

Authors:  Susan Moir; Angela Malaspina; Anthony S Fauci
Journal:  Nat Struct Mol Biol       Date:  2011-12-05       Impact factor: 15.369

4.  Crystal structure of human antibody 2909 reveals conserved features of quaternary structure-specific antibodies that potently neutralize HIV-1.

Authors:  Anita Changela; Xueling Wu; Yongping Yang; Baoshan Zhang; Jiang Zhu; Glenn A Nardone; Sijy O'Dell; Marie Pancera; Miroslaw K Gorny; Sanjay Phogat; James E Robinson; Leonidas Stamatatos; Susan Zolla-Pazner; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

5.  A conserved determinant in the V1 loop of HIV-1 modulates the V3 loop to prime low CD4 use and macrophage infection.

Authors:  Thomas Musich; Paul J Peters; Maria José Duenas-Decamp; Maria Paz Gonzalez-Perez; James Robinson; Susan Zolla-Pazner; Jonathan K Ball; Katherine Luzuriaga; Paul R Clapham
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

Review 6.  Editorial neuroAIDS review.

Authors:  Paul Shapshak; Pandjassarame Kangueane; Robert K Fujimura; Deborah Commins; Francesco Chiappelli; Elyse Singer; Andrew J Levine; Alireza Minagar; Francis J Novembre; Charurut Somboonwit; Avindra Nath; John T Sinnott
Journal:  AIDS       Date:  2011-01-14       Impact factor: 4.177

7.  Shedding-Resistant HIV-1 Envelope Glycoproteins Adopt Downstream Conformations That Remain Responsive to Conformation-Preferring Ligands.

Authors:  Maolin Lu; Xiaochu Ma; Nick Reichard; Daniel S Terry; James Arthos; Amos B Smith; Joseph G Sodroski; Scott C Blanchard; Walther Mothes
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

8.  Delivery strategies for novel vaccine formulations.

Authors:  Maria Trovato; Shelly J Krebs; Nancy L Haigwood; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2012-02-12

9.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Authors:  Nicos Karasavvas; Erik Billings; Mangala Rao; Constance Williams; Susan Zolla-Pazner; Robert T Bailer; Richard A Koup; Sirinan Madnote; Duangnapa Arworn; Xiaoying Shen; Georgia D Tomaras; Jeffrey R Currier; Mike Jiang; Craig Magaret; Charla Andrews; Raphael Gottardo; Peter Gilbert; Timothy J Cardozo; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Robert Paris; Kelli Greene; Hongmei Gao; Sanjay Gurunathan; Jim Tartaglia; Faruk Sinangil; Bette T Korber; David C Montefiori; John R Mascola; Merlin L Robb; Barton F Haynes; Viseth Ngauy; Nelson L Michael; Jerome H Kim; Mark S de Souza
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

10.  The V4 and V5 Variable Loops of HIV-1 Envelope Glycoprotein Are Tolerant to Insertion of Green Fluorescent Protein and Are Useful Targets for Labeling.

Authors:  Shuhei Nakane; Aikichi Iwamoto; Zene Matsuda
Journal:  J Biol Chem       Date:  2015-04-24       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.